(VIANEWS) – The NYSE ended the session with Edwards Lifesciences (EW) rising 9.74% to $86.38 on Friday while NYSE fell 0% to $17,115.75.
Edwards Lifesciences’s last close was $78.71, 17.03% under its 52-week high of $94.87.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Edwards Lifesciences has a trailing twelve months EPS of $2.34.
PE Ratio
Edwards Lifesciences has a trailing twelve months price to earnings ratio of 36.91. Meaning, the purchaser of the share is investing $36.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.06%.
Yearly Top and Bottom Value
Edwards Lifesciences’s stock is valued at $86.38 at 17:04 EST, below its 52-week high of $94.87 and way higher than its 52-week low of $60.57.
Sales Growth
Edwards Lifesciences’s sales growth is 10.8% for the current quarter and 7% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Edwards Lifesciences’s stock is considered to be oversold (<=20).
More news about Edwards Lifesciences (EW).
